Close Search

Products

Enter keywords

Related results

Peptide receptive HLA class I molecules allowing you to make your own custom peptide-HLA complexes.

HLA-A0203 easYmers®

Catalog no.
1005-01
Group
HLA-A
Alpha chain
HLA-A0203
Beta chain
b2m
Peptide
NLVPMVATV
Peptide source
CMV pp65 495-503
Format
easYmer
Storage
-20°C
Buffer
TRIS/MALEATE pH 7
Shelf life
18 Months
Application
easYmers® are peptide receptive HLA class I molecules which can be used to generate peptide HLA (pHLA) monomers with your choice of peptide. The monomers can easily be tetramerized with fluorophore conjugated streptavidin and used to analyse T cells by flowcytometry. The easYmer reagent can also be used to evaluate specific pHLA I interactions.
Concentration
3000 nM
For Research Use Only (RUO)

Published Research using immunAware reagents and services

01/05/2023

Journal of hepatology

Boosting compromised SARS-CoV-2-specific immunity with mRNA vaccination in liver transplant recipients

Liver transplant recipients (LTRs) demonstrate a reduced response to COVID-19 mRNA vaccination; however, a detailed understanding of the interplay between humoral and cellular immunity, especially after a third (and fourth) vaccine dose, is lacking.We longitudinally compared the humoral, as well as CD4+ and CD8+ T-cell, responses between LTRs (n = 24) and healthy controls (n = 19) after three (LTRs: n = 9 to 16; healthy controls: n = 9 to 14 per experiment) to four (LTRs: n = 4; healthy controls: n = 4) vaccine doses, including in-depth phenotypical and functional characterization.Compared to healthy controls, development of high antibody titers required a third vaccine dose in most LTRs, while spike-specific CD8+ T cells with robust recall capacity plateaued after the second vaccine dose, albeit with a reduced frequency and epitope repertoire compared to healthy controls. This overall attenuated vaccine response was linked to a reduced frequency of spike-reactive follicular T helper cells in LTRs.Three doses of a COVID-19 mRNA vaccine induce an overall robust humoral and cellular memory response in most LTRs. Decisions regarding additional booster doses may thus be based on individual vaccine responses as well as evolution of novel variants of concern.Due to immunosuppressive medication, liver transplant recipients (LTR) display reduced antibody titers upon COVID-19 mRNA vaccination, but the impact on long-term immune memory is not clear. Herein, we demonstrate that after three vaccine doses, the majority of LTRs not only exhibit substantial antibody titers, but also a robust memory T-cell response. Additional booster vaccine doses may be of special benefit for a small subset of LTRs with inferior vaccine response and may provide superior protection against evolving novel viral variants. These findings will help physicians to guide LTRs regarding the benefit of booster vaccinations.